Combination of plasma amyloid beta((1-42/1-40)) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology

BACKGROUND: Blood-based biomarkers for Alzheimer’s disease (AD) might facilitate identification of participants for clinical trials targeting amyloid beta (Abeta) accumulation, and aid in AD diagnostics. We examined the potential of plasma markers Abeta((1-42/1-40)), glial fibrillary acidic protein...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Alzheimers Res Ther
Asıl Yazarlar: Verberk, Inge M. W., Thijssen, Elisabeth, Koelewijn, Jannet, Mauroo, Kimberley, Vanbrabant, Jeroen, de Wilde, Arno, Zwan, Marissa D., Verfaillie, Sander C. J., Ossenkoppele, Rik, Barkhof, Frederik, van Berckel, Bart N. M., Scheltens, Philip, van der Flier, Wiesje M., Stoops, Erik, Vanderstichele, Hugo M., Teunissen, Charlotte E.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2020
Konular:
Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7523295/
https://ncbi.nlm.nih.gov/pubmed/32988409
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13195-020-00682-7
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller